COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ACTIVE CROHN'S DISEASE IN GREECE

被引：0
|
作者：
Vellopoulou, K. [1 ]
Lioliou, K. [1 ]
Papantoniou, P. [2 ]
Kotsis, I [2 ]
机构：
[1] Econcare LP, Athens, Greece
[2] AbbVie Hellas, Athens, Greece
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE94
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [11] COST-EFFECTIVENESS ANALYSIS OF PHARMACOLOGICAL TREATMENTS OF MODERATE-TO-SEVERE ALZHEIMER'S DISEASE
    Yunusa, I
    Rane, A.
    Sultan, I
    Eguale, T.
    VALUE IN HEALTH, 2020, 23 : S267 - S267
  • [12] COST-EFFECTIVENESS ANALYSIS OF BIMEKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Koulentaki, M.
    Tzanetakos, C.
    Stratigos, A.
    Sotiriou, E.
    Ladha, I
    Christou, P.
    Relakis, J.
    Kourlaba, G.
    VALUE IN HEALTH, 2022, 25 (12) : S74 - S74
  • [13] Upadacitinib for the treatment of moderate to severe Crohn's disease
    Kessing, Richard
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2024, 62 (01): : 25 - 25
  • [14] BUDGET IMPACT ANALYSIS OF BIMEKIZUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Koulentaki, M.
    Tzanetakos, C.
    Stratigos, A.
    Sotiriou, E.
    Ladha, I
    Kountouris, V
    Relakis, J.
    Kourlaba, G.
    VALUE IN HEALTH, 2022, 25 (12) : S185 - S185
  • [15] Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden
    Hansson-Hedblom, Amanda
    Almond, Chrissy
    Borgstrom, Fredrik
    Sly, Indeg
    Enkusson, Dana
    Buchholt, Anders Troelsgaard
    Karlsson, Linda
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2018, 16
  • [16] Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
    Amanda Hansson-Hedblom
    Chrissy Almond
    Fredrik Borgström
    Indeg Sly
    Dana Enkusson
    Anders Troelsgaard Buchholt
    Linda Karlsson
    Cost Effectiveness and Resource Allocation, 16
  • [17] Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece
    Vellopoulou, Katerina
    Stefanou, Garyfallia
    Tzanetakos, Charalampos
    Boubouchairopoulou, Nantia
    Nakou, Magdalini
    Gourzoulidis, George
    Kourlaba, Georgia
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (03) : 325 - 333
  • [18] COST-UTILITY AND BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE FOR THE TREATMENT OF MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS IN GREECE
    Maniadakis, N.
    Boumpas, D.
    Kourlaba, G.
    Christou, P.
    Anargiros, I
    Smets, E.
    Purcaru, O.
    VALUE IN HEALTH, 2011, 14 (07) : A310 - A310
  • [19] Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China
    Xu, Xinyi
    Geng, Linyu
    Xu, Xue
    Huang, Saisai
    Liang, Jun
    IMMUNOTHERAPY, 2024,
  • [20] A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece
    Nomikos, Nikolaos
    Eleftheriou, Christos
    Athanasakis, Kostas
    TOXINS, 2023, 15 (09)
12345